

WESTLAKE CHEMICAL CORP  
Form 8-K  
July 17, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (date of earliest event reported): July 17, 2014**

**WESTLAKE CHEMICAL CORPORATION**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
**of incorporation)**

**001-32260**  
**(Commission**  
**File Number)**

**76-0346924**  
**(I.R.S. employer**  
**Identification No.)**

**2801 Post Oak Boulevard, Suite 600**

**77056**

**Houston, Texas**

**(Address of principal executive offices)**

**(Zip Code)**

**Registrant's telephone number, including area code: (713) 960-9111**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.01. Entry into a Material Definitive Agreement.**

On July 17, 2014, Westlake Chemical Corporation and certain of its subsidiaries (collectively, the Company ) entered into a third amendment and restatement (the Amendment and Restatement ) of the Second Amended and Restated Credit Agreement dated as of September 16, 2011, as heretofore amended (as so amended, the Revolving Credit Agreement ), by and among the financial institutions party thereto, as lenders (collectively, the Lenders ), Bank of America, N.A., as agent, and Westlake Chemical Corporation and certain of its subsidiaries, as borrowers, relating to a \$400 million senior secured revolving credit facility.

Among other things, the Amendment and Restatement:

extended the scheduled maturity date of the facility from September 16, 2016 to July 17, 2019;

reduced the interest rate and facility fee payable under the Revolving Credit Agreement;

includes a covenant requiring the Company to maintain a minimum fixed charge coverage ratio of 1.0:1.0 for successive 30-day periods after any date on which the borrowing availability under the facility is less than the greater of (1) 10% of the commitments under the facility and (2) \$40 million, until the borrowing availability exceeds the greater of the amount in clause (1) and the amount in clause (2) for a 30-business day period;

includes a covenant generally restricting the Company from making distributions unless, on a pro forma basis after giving effect to the distribution, the borrowing availability under the facility equals or exceeds the greater of (1) 20% of the commitments under the facility and (2) \$80 million; or the borrowing availability under the facility equals or exceeds the greater of (1) 15% of the commitments under the facility and (2) \$60 million, and the Company's fixed charge coverage ratio is at least 1.0:1.0; provided, that, notwithstanding the foregoing, the Company may make distributions in the aggregate up to \$75 million, to be increased by 5% in 2015, and in each fiscal year thereafter, on an aggregate basis, for each fiscal year;

includes a covenant generally restricting the Company from making acquisitions and investments unless, on a pro forma basis after giving effect to the acquisition or investment, the borrowing availability under the facility equals or exceeds the greater of (1) 15% of the commitments under the facility and (2) \$60 million; or the borrowing availability under the facility equals or exceeds the greater of (1) 12.5% of the commitments under the facility and (2) \$50 million, and the Company's fixed charge coverage ratio is at least 1.0:1.0; provided, that, notwithstanding the foregoing, the Company may make investments in the aggregate up to the greater of \$50 million and 1.25% of tangible assets and acquisitions in the aggregate up to the greater of \$100 million and 2.5% of tangible assets, if, on a pro forma basis after giving effect to the acquisition or investment, either (1) the borrowing availability under the facility equals or exceeds the greater of (A) 12.5% of the commitments under the facility and (B) \$50 million, or (2) the Company's fixed charge coverage ratio is at least 1.0:1.0;

generally allows the Company to incur up to the greater of \$300 million and 7.5% of tangible assets in purchase money debt;

Edgar Filing: WESTLAKE CHEMICAL CORP - Form 8-K

generally allows the Company to incur an unlimited amount of debt secured by liens on assets of the Company that are not collateral under the facility;

permits the Company to enter into and consummate the transactions described in the S-1 filed with the Commission by Westlake Chemical Partners LP on April 29, 2014, relating to the initial public offering of a master limited partnership.

- 2 -

The Revolving Credit Agreement also includes a provision permitting the borrowers to increase the size of the facility, up to four times, in increments of at least \$25 million each (up to a maximum of \$200 million) under certain circumstances if certain lenders agree to commit to such an increase.

Amounts drawn under the facility are limited to (1) 85% of the net amount of eligible accounts receivable, plus (2) the lesser of (a) 70% of the value of the lower of cost or market of eligible inventory, or (b) 85% of the appraised net orderly liquidation value of all eligible inventory, plus (3) 100% of cash held in an account with Bank of America and subject to a control agreement with Bank of America, minus (4) such reserves as Bank of America, the agent, may establish. The facility includes a \$400 million sub-limit for letters of credit, and any outstanding letters of credit will be deducted from availability under the facility.

Any borrowings under the facility will bear interest at either LIBOR plus a spread ranging from 1.75% to 1.25%, provided that so long as the Company is rated investment grade, the margin for LIBOR loans will not exceed 1.50%, or a base rate plus a spread ranging from 0.50% to 0.00%. The revolving credit facility also requires an unused commitment fee of 0.25%. All interest rates under the facility are subject to monthly grid pricing adjustments based on prior month average daily loan availability.

The Amendment and Restatement is filed as Exhibit 10.1 to this report and is incorporated herein by reference. The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the Amendment and Restatement.

**Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

The information set forth in Item 1.01 above is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

The following exhibit is furnished herewith:

10.1 Third Amended and Restated Credit Agreement dated as of July 17, 2014, by and among the financial institutions party thereto, as lenders, Bank of America, N.A., as agent, and Westlake and certain of its domestic subsidiaries, as borrowers, relating to a \$400 million senior secured revolving credit facility.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized

**WESTLAKE CHEMICAL  
CORPORATION**

By: /s/ Albert Chao  
Albert Chao  
President and Chief Executive Officer

Date: July 17, 2014

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
10.1	Third Amended and Restated Credit Agreement dated as of July 17, 2014, by and among the financial institutions party thereto, as lenders, Bank of America, N.A., as agent, and Westlake and certain of its domestic subsidiaries, as borrowers, relating to a \$400 million senior secured revolving credit facility